questionsmedicales.fr
États, signes et symptômes pathologiques
Signes et symptômes
Manifestations neurologiques
Paralysie
Hémiplégie
Hémiplégie : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémiplégie : Questions médicales les plus fréquentes",
"headline": "Hémiplégie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémiplégie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-23",
"dateModified": "2025-02-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémiplégie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Paralysie",
"url": "https://questionsmedicales.fr/mesh/D010243",
"about": {
"@type": "MedicalCondition",
"name": "Paralysie",
"code": {
"@type": "MedicalCode",
"code": "D010243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.636"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémiplégie",
"alternateName": "Hemiplegia",
"code": {
"@type": "MedicalCode",
"code": "D006429",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohamad A Mikati",
"url": "https://questionsmedicales.fr/author/Mohamad%20A%20Mikati",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pediatric Neurology, Duke University Health System, Duke University School of Medicine, Durham NC. mohamad.mikati@dm.duke.edu."
}
},
{
"@type": "Person",
"name": "Lyndsey Prange",
"url": "https://questionsmedicales.fr/author/Lyndsey%20Prange",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pediatric Neurology, Duke University Health System, Duke University School of Medicine, Durham NC."
}
},
{
"@type": "Person",
"name": "Julie Uchitel",
"url": "https://questionsmedicales.fr/author/Julie%20Uchitel",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pediatric Neurology, Duke University Health System, Duke University School of Medicine, Durham NC."
}
},
{
"@type": "Person",
"name": "April Boggs",
"url": "https://questionsmedicales.fr/author/April%20Boggs",
"affiliation": {
"@type": "Organization",
"name": "Division of Pediatric Neurology and Developmental Medicine, Duke University, Durham, NC, USA."
}
},
{
"@type": "Person",
"name": "Milton Pratt",
"url": "https://questionsmedicales.fr/author/Milton%20Pratt",
"affiliation": {
"@type": "Organization",
"name": "Division of Pediatric Neurology and Developmental Medicine, Duke University, Durham, NC, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.",
"datePublished": "2023-04-26",
"url": "https://questionsmedicales.fr/article/36930250",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1530/ERC-22-0395"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.",
"datePublished": "2022-07-06",
"url": "https://questionsmedicales.fr/article/35803176",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2022.06.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.",
"datePublished": "2022-06-28",
"url": "https://questionsmedicales.fr/article/35762209",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ans.17851"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35895181",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12020-022-03114-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Progress in the Treatment of Small Intestine Cancer.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36826686",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11864-023-01058-3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Paralysie",
"item": "https://questionsmedicales.fr/mesh/D010243"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hémiplégie",
"item": "https://questionsmedicales.fr/mesh/D006429"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémiplégie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémiplégie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémiplégie",
"description": "Comment diagnostique-t-on l'hémiplégie ?\nQuels tests sont utilisés pour évaluer l'hémiplégie ?\nL'électromyographie est-elle utile ?\nQuels signes cliniques indiquent l'hémiplégie ?\nL'hémiplégie peut-elle être confondue avec d'autres conditions ?",
"url": "https://questionsmedicales.fr/mesh/D006429?mesh_terms=Intestinal+Neoplasms&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémiplégie",
"description": "Quels sont les symptômes de l'hémiplégie ?\nL'hémiplégie affecte-t-elle la sensibilité ?\nPeut-on avoir des douleurs avec l'hémiplégie ?\nY a-t-il des troubles cognitifs associés ?\nL'hémiplégie peut-elle causer des problèmes émotionnels ?",
"url": "https://questionsmedicales.fr/mesh/D006429?mesh_terms=Intestinal+Neoplasms&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémiplégie",
"description": "Comment prévenir l'hémiplégie ?\nL'exercice régulier aide-t-il ?\nUne alimentation saine est-elle importante ?\nFaut-il éviter le tabac ?\nLe stress peut-il influencer le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006429?mesh_terms=Intestinal+Neoplasms&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémiplégie",
"description": "Quels traitements sont disponibles pour l'hémiplégie ?\nLa physiothérapie est-elle efficace ?\nDes médicaments sont-ils prescrits ?\nLa chirurgie est-elle une option ?\nQuelles sont les approches complémentaires ?",
"url": "https://questionsmedicales.fr/mesh/D006429?mesh_terms=Intestinal+Neoplasms&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémiplégie",
"description": "Quelles complications peuvent survenir ?\nL'hémiplégie peut-elle entraîner des problèmes respiratoires ?\nY a-t-il un risque de thrombose ?\nDes troubles de la peau peuvent-ils se développer ?\nL'hémiplégie peut-elle affecter la santé mentale ?",
"url": "https://questionsmedicales.fr/mesh/D006429?mesh_terms=Intestinal+Neoplasms&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémiplégie",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie influence-t-il le risque ?\nLe stress est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D006429?mesh_terms=Intestinal+Neoplasms&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on l'hémiplégie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et des imageries cérébrales comme l'IRM."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'hémiplégie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests neurologiques et des évaluations fonctionnelles sont utilisés pour mesurer la gravité."
}
},
{
"@type": "Question",
"name": "L'électromyographie est-elle utile ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer la fonction musculaire et la conduction nerveuse."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent l'hémiplégie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent une faiblesse unilatérale, des réflexes anormaux et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "L'hémiplégie peut-elle être confondue avec d'autres conditions ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres troubles neurologiques comme l'hémiparésie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hémiplégie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une paralysie d'un côté, des troubles de la parole et des difficultés motrices."
}
},
{
"@type": "Question",
"name": "L'hémiplégie affecte-t-elle la sensibilité ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des pertes de sensation ou des sensations anormales du côté affecté."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des douleurs avec l'hémiplégie ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs neuropathiques ou musculo-squelettiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des troubles cognitifs associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles cognitifs peuvent survenir, affectant la mémoire et la concentration."
}
},
{
"@type": "Question",
"name": "L'hémiplégie peut-elle causer des problèmes émotionnels ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes comme la dépression et l'anxiété sont fréquents après un AVC."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hémiplégie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le contrôle des facteurs de risque comme l'hypertension et le diabète."
}
},
{
"@type": "Question",
"name": "L'exercice régulier aide-t-il ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire le risque d'accidents vasculaires cérébraux."
}
},
{
"@type": "Question",
"name": "Une alimentation saine est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée aide à maintenir une bonne santé cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Faut-il éviter le tabac ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque d'AVC et d'hémiplégie."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des problèmes de santé augmentant le risque d'AVC."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'hémiplégie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la rééducation physique, l'ergothérapie et des médicaments."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie aide à améliorer la mobilité et la force musculaire."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils prescrits ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les anticoagulants ou les anti-inflammatoires peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, la chirurgie peut être envisagée pour traiter des complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les approches complémentaires ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme l'acupuncture ou la thérapie par le mouvement peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des problèmes de déglutition et des contractures."
}
},
{
"@type": "Question",
"name": "L'hémiplégie peut-elle entraîner des problèmes respiratoires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes respiratoires peuvent survenir en raison de la faiblesse musculaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de thrombose ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de thrombose veineuse profonde est accru chez les patients hémiplégiques."
}
},
{
"@type": "Question",
"name": "Des troubles de la peau peuvent-ils se développer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des escarres peuvent se former en raison d'une immobilité prolongée."
}
},
{
"@type": "Question",
"name": "L'hémiplégie peut-elle affecter la santé mentale ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles mentaux comme la dépression sont fréquents après un AVC."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'hypertension, le diabète, le tabagisme et l'obésité."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'hémiplégie augmente avec l'âge, surtout après 55 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'AVC augmentent le risque d'hémiplégie."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des problèmes cardiovasculaires et d'AVC."
}
}
]
}
]
}
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of t...
Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic facto...
This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) we...
In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic ...
These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in pati...
Small intestinal Neuroendocrine Neoplasms (SI-NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI-NEN in Auckland, A...
A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify th...
One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%)...
This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence...
Bcl-2 family proteins are of great significance in the pathogenesis and development of tumors. In this study, the correlations between the expression of Bcl-2 family proteins and clinicopathological f...
105 Patients diagnosed with gastroenteropancreatic NENs (GEP-NENs) with the paraffin specimen of the tumor available were retrospectively included. Immunohistochemistry (IHC) was performed to detect t...
The IHC score of Bcl-2 was significantly higher in neuroendocrine carcinoma (NEC) patients (65.6%), while a higher IHC score of Noxa was more common in neuroendocrine tumor (NET) patients (49.3%). Sur...
Higher expression of Bcl-2 and lower expression of Noxa were associated with unfavorable prognosis of GEP-NENs patients....
Small intestine cancer is rare, accounting for approximately 3% of all gastrointestinal malignancies. The most common histological subtypes include adenocarcinoma, neuroendocrine tumours (NETs) and ga...
To determine the effectiveness and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) and provide evidence-based suggestions for clinical treatment....
The Cochrane Library, Embase, PubMed, and Web of Science were searched for articles published that analyzed the effectiveness and safety of GEP-NEN-targeted neoadjuvant therapy before March 2023. A co...
A total of 417 patients from 13 studies were included in this meta-analysis. The primary variables comprised the objective response rate (ORR), disease control rate (DCR), surgical resection rate, and...
Neoadjuvant therapy is an effective and safe treatment method for GEP-NENs. However, further studies are required to determine the optimal regimen for this therapy in these tumors....
High-grade (grade 3) neuroendocrine neoplasms (G3 NENs) have poor survival outcomes. From a clinical standpoint, G3 NENs are usually grouped regardless of primary site and treated similarly. Little is...
Gastroenteropancreatic NEN (GEP-NEN) are group of malignancies with significant clinical, anatomical and molecular heterogeneity. High-grade GEP-NEN in particular present unique management challenges....
In the current era, multidisciplinary management with access to a combination of functional imaging and targeted molecular profiling can provide important disease characterisation, guide individualise...
Histopathological classifications of neuroendocrine neoplasms (NEN) change regularly and the latest WHO classification published in 2022, which concerns all NEN in the body, attempts to standardize cl...
High-grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of rare tumors of two different types: well differentiated neuroendocrine tumors grade 3 (NETs G3) and ...
Seventy-two patients diagnosed with high-grade GEP-NENs who underwent surgery at our institution were recruited for this study. Demographic and clinicopathological characteristics, preoperative serum ...
Serum carcinoembryonic antigen (CEA) was dramatically higher in NECs than in NETs G3 (P = 0.025). After follow-up, 57 of the 72 patients remained for survival analysis. Elevated serum carbohydrate ant...
Serum CEA levels can be used to distinguish NETs G3 from NECs. Preoperative CA19-9, CEA, cancer antigen 125 and SA levels have predictive value in the prognosis of high-grade GEP-NENs. Preoperative CA...